Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clinical setbacks for candidates targeting the LAG-3 ...
May 18, 2026 06:34 AM EDT R&DPharma Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3 Ayisha Sharma News Reporter Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that